Biofrontera AG signs distribution agreement for Ameluz with Propharma in Croatia
Biofrontera AG has signed a distribution agreement with Propharma d.o.o. for the commercialization of Ameluz® in Croatia. Propharma will seek reimbursement for the product, with sales expected to begin by the end of 2026, pending successful reimbursement discussions. Ameluz® is used to treat mild to moderate actinic keratosis and superficial/nodular basal cell carcinoma in adults.
Biofrontera AG announced that its main commercial subsidiary, Biofrontera Pharma GmbH, has entered into a promotion and distribution agreement with Propharma d.o.o. for the commercialization of Ameluz® in Croatia. Under the agreement, Propharma d.o.o. will seek reimbursement for Ameluz® and, subject to a successful outcome of reimbursement discussions, is expected to begin selling the product towards the end of 2026. Ameluz® is indicated for the treatment of mild to moderate actinic keratosis and superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment in adults. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
